AstraZeneca trial participant who had adverse reaction experienced transverse myelitis, safety report shows

More posts on drug store: Drug costs surge faster than any other medical great or service, data showsEli Lilly, Amgen partner to make Lillys COVID-19 antibody drugModerna will know if COVID-19 vaccine works in November, CEO says.

AstraZeneca announced it had taken a “voluntary pause” of its stage 3 COVID-19 vaccine trial Sept. 9 after a previously healthy 37-year-old lady experienced a negative response. The drugmaker resumed the trial in the U.K. Sept. 12 after acquiring approval from the Medicines Health Regulatory Authority, the nations equivalent of the FDA, however has yet to continue the trial in the U.S

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.

. The file states the individual “knowledgeable confirmed transverse myelitis,” a rare neurological condition in which the back cord ends up being swollen, and was hospitalized on Sept. 5. It also detailed the individuals signs, which included weakness, reduced motor functions and pain in her arms.

The lady who experienced an extreme adverse response after getting a COVID-19 vaccine while getting involved in AstraZenecas U.K. trial had transverse myelitis, according to an internal security report gotten by CNN.

Katie Adams –
Friday, September 18th, 2020
Print|Email.

The report was issued to doctors running AstraZenecas trials Sept. 11.